Zaltrap aflibercept regulatory update

FDA accepted and granted Priority Review to a resubmitted BLA for Zaltrap aflibercept for the second-line treatment of metastatic colorectal cancer (mCRC). The PDUFA date is Aug. 4. Sanofi withdrew th...